Main Article Content
Abstract
A B S T R A C T
Systemic sclerosis is characterized by extensive and progressive organ
fibrosis processes leading to organ failure and death. Modified Rodnan Skin
Score (mRSS) had been used as a clinical parameter of skin fibrosis. Anti-
topoisomerase I and C-Reactive Protein (CRP) are potential biomarkers for
assessing disease activity. The study was performed to determine the
association of anti-topoisomerase I and CRP antibodies with mRSS values.
We performed an observational analytic study based on primary and
secondary data. Systemic sclerosis patient sera data was obtained from
Dewi S et al's study, taken from May 2015 to June 2017. Serum Anti -
topoisomerase I antibody and CRP level analysis were performed in
December 2017.
Fifty six samples analyzed. Fifty four subjects (96.4%) out of 56 subjects are
women with an average age of 37 ± 11 years, 41 subjects (73.3%) has
disease duration over 2 years, 34 subjects (60.7%) has difuse systemic
sclerosis, 41 subjects (73.3%) in steroid therapy and 50 subjects (89.3%) in
methotrexate therapy. The statistical analysis showed no correlation
between anti-topoisomerase I antibody and CRP levels with mRSS values
(r = 0.205, p = 0.064; r = -0.134, p = 0.167), but there was a positive
correlation of anti-topoisomerase I antibody level with mRSS (r = 0,422 p =
0,007) and negative correlation between CRP level and mRSS (r = -0,511 p
= 0,001) in diffuse sclerosis systemic.
From this study we concluded that anti-topoisomerase I antibody and CRP
level were not correlated with mRSS, but in patient with diffuse systemic
sclerosis there was a positive correlation of anti-topoisomerase I antibody
level with mRSS and negative correlation between CRP level and mRSS.